Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Merck, Eisai win FDA approval for Welireg-Lenvima in advanced RCC

25 September 2026 · By · Wire by Fusion42

Published

25 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 25 September 2026 · Fusion42 review

Merck and Eisai received US FDA approval for Welireg (belzutifan) combined with Lenvima (lenvatinib) to treat adults with advanced clear cell renal cell carcinoma after prior PD-1 or PD-L1 inhibitor therapy, marking the first approval for a HIF-2α inhibitor plus VEGFR tyrosine kinase inhibitor combo in this setting.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

Your oncology development in renal cell carcinoma now must address competition from a novel dual-targeted oral therapy combining HIF-2α and VEGFR inhibition, reshaping treatment standards especially after immune checkpoint inhibitors.

◆ Coverage

2 sources · 25 Sep 2026

◆ Related on Wire

◆ Topics

Biotechrenal-cell-carcinomaFDA-approvaloncologycombination-therapydrug-safety